The average number of new Covid-19 cases being reported in the U.S. continued to edge up, as a federal pause on Johnson & Johnson’s Covid-19 vaccine was kept in place.
The seven-day average of newly reported cases was 71,282 on Wednesday, up from 53,678 a month ago, according to a Wall Street Journal analysis of data compiled by Johns Hopkins University. Not all states report data on new cases daily, and the weekly average helps smooth out those differences in data reporting.
On Wednesday, the U.S. reported 75,375 new cases, according to Johns Hopkins data, down slightly from 77,878 a day earlier.
While the seven-day average is sharply down from peaks near 250,000 in January, it has been climbing in recent weeks. More than half of states are seeing a higher seven-day average than 14-day average, which signals a rise in infections. The upper Midwest and parts of the Northeast in particular are recording larger caseloads.
Hospitalizations have also been rising recently, with 45,308 Covid-19 patients in hospitals around the U.S., according to the latest data posted by the Department of Health and Human Services. That figure had flattened out at around 40,000 in March, following a steady, monthslong decline from a January peak above 140,000, according to HHS data.
The country reported 956 Covid-19 fatalities for Wednesday, as the total death toll topped 564,400, according to Johns Hopkins data.
The rise in cases and hospitalizations comes as federal and state officials push to get more shots in American arms. An average of 3.3 million doses of Covid-19 vaccine were administered each day over the past week, according to a Wall Street Journal analysis of Centers for Disease Control and Prevention data.
About 23.1% of U.S. residents are now fully vaccinated, while 37.3% have received at last one dose of a vaccine. Vaccination levels vary by state. In New Hampshire, more than half of residents have received at least one shot, while in Mississippi, the figure is 28.4%.
The federal government’s recommendation to pause using Johnson & Johnson’s Covid-19 vaccine will remain in place after an advisory panel put off a vote on how to move forward following reports of a few cases of life-threatening blood clots.
The Advisory Committee on Immunization Practices, or ACIP, said Wednesday it doesn’t have enough information yet about the risk of these unusual side effects to determine whether the vaccine should be continued, discontinued or recommended only for certain groups of the population. The ACIP expects to meet again in another week or two to revisit the issue.
The delay shouldn’t pose a problem to vaccinations, the members said, because supplies of other vaccines are available.
Meanwhile, an updated analysis of a large clinical trial showed that Moderna's Covid-19 vaccine was more than 90% effective at preventing Covid-19 disease in people six months after vaccination. The updated efficacy figure, based on more than 900 cases of Covid-19 among study subjects, was largely in line with the 94.1% efficacy that Moderna had reported late last year based on 196 Covid-19 cases in the same 30,000-person study. The vast majority of the cases were in people who had gotten a placebo, showing the vaccine was protective.
Moderna also said its vaccine was 95% protective against severe Covid-19 in the updated analysis. The company reported the new numbers in a press release and the findings haven’t yet been published in a peer-reviewed scientific journal.
"case" - Google News
April 16, 2021 at 02:03AM
https://ift.tt/2RyVehn
Covid-19 Live Updates: U.S. Case Average Trends Higher - The Wall Street Journal
"case" - Google News
https://ift.tt/37dicO5
Shoes Man Tutorial
Pos News Update
Meme Update
Korean Entertainment News
Japan News Update
Bagikan Berita Ini
0 Response to "Covid-19 Live Updates: U.S. Case Average Trends Higher - The Wall Street Journal"
Post a Comment